通过重叠分析,研究环境暴露对肌肉缩小性侧面硬化症病理学的潜在作用
Nazli Sila Kara1, Ozan Ozisik2, Anaïs Baudot3,4
1Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia, Czechia.
Neurotoxicity research
|December 12, 2025
概括
吸烟和农药等环境暴露可能通过影响细胞机制增加肌缩侧面硬化症 (ALS) 风险. 这项研究揭示了神经毒性暴露和ALS病理学之间的共同分子通路,为疾病发展提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 环境健康 环境健康
- 生物信息学是一种生物信息学.
背景情况:
- 肌缩侧面硬化 (ALS) 是一种进展性神经退行性疾病,其特征是运动神经元损失.
- 散发性ALS,占90-95%的病例,涉及遗传和环境因素.
- 吸烟,农药和溶剂等神经毒性暴露被怀疑是导致ALS风险的因素,但它们的特定细胞影响仍然不清楚.
研究的目的:
- 调查柴油废气,烯,农药和吸烟对ALS病理学的潜在毒性机制.
- 通过生物信息学方法确定环境暴露和ALS之间的共享分子途径.
- 为分析神经退行性疾病中的暴露与疾病相互作用提供一个框架.
主要方法:
- 利用生物信息学的方法来分析基因组.
- 通过环境暴露 (柴油废气,烯,农药,吸烟) 准的基因组被检索出来.
- 在环境暴露基因组和ALS相关的生物过程基因组之间进行了重叠分析.
主要成果:
- 在所有四种暴露和与ALS相关的过程之间发现了显著的重叠,包括氧化应激反应,突触信号传递,脂质代谢和质生成.
- 特定的途径,如伴侣介导的自,DNA修复和动作潜能调节,与某些暴露 (柴油废气,农药,烯) 显示出独特的重叠.
- 烟草烟雾污染与与血脑屏障运输,囊泡运输,基于actin的运输,自,蛋白质修饰,脂质代谢,神经递质调节和轴突引导相关的途径具有独特的重叠.
结论:
- 环境神经毒性暴露与肌缩侧面硬化症具有共同和独特的分子途径.
- 了解这些分子关系对于阐明ALS的发病过程至关重要.
- 这种重叠分析框架可用于研究神经退行症中的其他暴露-疾病相互作用.
更多相关视频
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.9K
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.7K
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
